The Government of the United States of America As Represented by the Secretary of the Deptartment of Health and Human Services

Globeimmune, Inc.

The Dow Chemical Company

The United States of America As Represented by the Department of Health

The United States of America As Represented by the Secretary of

Therion Biologics Corporation

Other

Dana-farber-cancer Institute Inc.

National Institutes of Health

Globelimmune, Inc.

Jeffrey Schlom

Kwong-Yok Tsang

Eduardo Agustin Padlan

James W Hodge

Claudia M Palena

Syed V S Kashmiri

Dennis L Panicali

Zhimin Guo

Alex Franzusoff

Sam Zaremba

David Apelian

Peter S Mezes

Judith A Kantor

Mark W Rixon

Linda R Gritz

Donald A Kaplan

Brian B Gourlie

Ira H Pastan

Gail P Mazzara

Elene Barzaga

Liming Shu

Kimberly S Johnson

Ruth A Richard

David Colcher

Scott Abrams

W H Anderson

Andrei P Kozlov

Donald W Kufe

Thomas H King

W H Kerr Anderson

Timothy C Rodell

Christopher Campbell

Faye Austin

Patricia H Hand

Marianna Nuti

Jeffrey Gildersleeve

James Gulley

Rafia Mehdi Kashmiri, Legal Representative

James Hodge

Jianping Huang

Syed Kashmiri

Syed V Kashmiri

Oyindasola Oyelaran

Syed Kasmiri

Erik Kass

John W Greiner

Claudia Palena

The invention provides a human cytotoxic T lymphocyte (CTL) agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), and/or in vaccine or other composition for the prevention or therapy of cancer. The invention further provides a nucleic acid encoding the peptide, protein, or polypeptide, a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide, nucleic acid, or vector, and compositions thereof.

HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use

Disclosed are immunotherapeutic compositions and the concurrent use of combinations of such compositions for the improved induction of therapeutic immune responses and/or for the prevention, amelioration and/or treatment of disease, including, but not limited to, cancer and infectious disease.

Combination immunotherapy compositions against cancer and methods

The invention provides Brachyury deletion mutant polypeptides, nucleic acids encoding the polypeptides, non-yeast vectors comprising the nucleic acids, non-yeast cells, and methods of use.

Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use

Disclosed are yeast-based immunotherapeutic compositions comprising Brachyury antigens, and methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of Brachyury.

Yeast-brachyury immunotherapeutic compositions

Brachyury protein can be used to induce Brachyury-specific CD4+ T cells in vivo and ex vivo. It is also disclosed that Brachyury protein can be used to stimulate the production of both Brachyury-specific CD4+ T cells and Brachyury-specific CD8+ T cells in a subject, such as a subject with cancer. In some embodiments, the methods include the administration of a Brachyury protein. In additional embodiments, the methods include the administration of a nucleic acid encoding the Brachyury protein, such as in a non-pox non-yeast vector. In further embodiments, the method include the administration of host cells expressing the Brachyury protein.

Brachyury protein, non-poxvirus non-yeast vectors encoding Brachyury protein, and their use

The invention provides HPV agonist epitopes, which can be used as a peptide, polypeptide (protein), and/or in a vaccine or other composition for the prevention or therapy of HPV infection and/or cancer. The invention further provides a nucleic acid encoding the peptide or polypeptide (protein), a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide (protein), nucleic acid, or vector, and compositions thereof.

Development of agonist epitopes of the human papillomavirus

Disclosed are improved yeast-based immunotherapeutic compositions comprising modified Brachyury antigens, and methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of Brachyury.

Modified yeast-brachyury immunotherapeutic compositions

Disclosed are yeast-based immunotherapeutic compositions comprising mucin-1 (MUC1), as well as methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of mucin-1 (MUC1).

Yeast-MUC1 immunotherapeutic compositions and uses thereof

Brachyury deletion mutants, non-yeast vectors encoding Brachyury deletion mutants, and their use

Growing community of inventors

Potomac, MD, United States of America

Jeffrey Schlom